GlassScriptPhysician profile
Larry S Bornstein
NPI 1548343577
$662,741.01
in general payments reported to CMS, 2019-2025
7 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242K · 2020: $73K · 2021: $11K · 2022: $41K · 2023: $142K · 2024: $126K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $254K · Travel and Lodging: $35K · Food and Beverage: $6,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $253,660.13 |
| Travel and Lodging | $35,213.73 |
| Food and Beverage | $6,240.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $526,548.56 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $113,775.53 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $16,392.44 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $3,818.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $2,058.69 | 2019 | |
| Alkermes, INC. | $119.92 | 2023 | Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $27.48 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Bornstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.